Ovid Therapeutics (OVID) may be one step closer to vindication with a rare disease treatment whose polarizing results led Wall Street to all but abandon the small drug company.

After a meeting with the Food and Drug Administration, Ovid is taking its therapy for the debilitating Angelman syndrome into a late-stage trial, one that will use the same definition of success employed in a prior study. The company said Thursday that the FDA agreed with its approach to determining whether Angelman patients are getting better. And that means Ovid could win FDA approval by replicating what it saw in an earlier trial.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy